The company specializes in developing monoclonal antibodies that modify and amplify signals from biomolecules, such as cytokines and cytokine receptors, to regulate the function of immune cells. By doing so, Selecxine aims to improve the survival rate and quality of life of cancer patients. They utilize an innovative platform technology for antibody development and screening to create safe and efficient therapeutics.